Therapeutic options in an immunocompromised patient with pemphigus vulgaris: Potential interest of plasmapheresis and extracorporeal photochemotherapy

European Journal of Dermatology

Volumn 18, Issue 3, 2008, Pages 354-356

  Saraceno, Rosita ^a   Ruzzetti, Manuela ^a   Lanti, Alessandro ^b   Marinacci, Monica ^b   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MEPREDNISONE; SULFAMETHIZOLE; TRIMETHOPRIM;

ABSCESS; ADL DISABILITY; ADULT; CASE REPORT; FACE; GENERAL CONDITION DETERIORATION; HUMAN; IMMUNOCOMPROMISED PATIENT; LETTER; LIMB; MALE; NOCARDIOSIS; ORAL BLISTER; PEMPHIGUS VULGARIS; PHOTOCHEMOTHERAPY; PLASMAPHERESIS; PLEURA EMPYEMA; QUALITY OF LIFE; SCALP; SKIN MANIFESTATION; TRUNK; WALKING AID;

HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; PEMPHIGUS; PHOTOPHERESIS; PLASMAPHERESIS; SKIN;

EID: 44949162955     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0415     Document Type: Letter

References (8)

1. Carducci M, Nosotti L, Calcaterra R, Bonifati C, Mussi A, Pelagalli L, Di Emidio L, Laurenzi L, Russo A, Franco G, Toma L, Morrone A. Early development of disseminated nocardiosis during immunosuppressive treatment for pemphigus vulgaris. Eur J Dermatol 2007; 17: 346-7.
2. Bystryn JC, Rudolph JL. Pemphigus. Lancet 2005; 366: 61-73.
3. Rouieau JC. Plasmapheresis therapy of pemphigus and bullous pemphigoid. Semin Dermatol 1988; 7: 195-200.
4. Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity 2006; 39: 609-16.
5. Rook AH, Cohen JH, Lessin SR, Vowels BR. Therapeutic applications of photopheresis. Dermatol Clin 1993; 11: 339-47.
6. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol 2005; 6: 327-42.
7. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, Kanamori H, Tanaka J, Asaka M, Imamura M, Masauzi N. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-9.
8. Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053-6.